The Role of Artificial Intelligence in Endoscopic Diagnosis of Esophagogastric Junctional Adenocarcinoma：A Single Center, Case-control, Diagnostic Study

Launched by QILU HOSPITAL OF SHANDONG UNIVERSITY · Apr 6, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how artificial intelligence (AI) can help doctors detect a specific type of cancer known as esophagogastric junctional adenocarcinoma, which affects the area where the esophagus meets the stomach. Researchers at Qilu Hospital will analyze images taken during endoscopy—a procedure where a flexible tube with a camera is used to look inside the gastrointestinal tract. The goal is to create an AI model that can not only identify this cancer from the images but also assess how deeply it has invaded surrounding tissues. They will compare the AI's findings to those of experienced doctors to see how well it assists in making a diagnosis.

To participate in this study, individuals should be at least 18 years old and have had endoscopic examinations. Those in the "case group" must have a confirmed diagnosis of esophagogastric junctional adenocarcinoma, while participants in the "control group" should have benign (non-cancerous) conditions confirmed by specialists. Those who have had prior treatments or surgeries for this type of cancer, or whose images are of poor quality, will not be eligible. While the study is not yet recruiting participants, it aims to gather valuable data that could enhance cancer detection in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • This study included endoscopic images of patients aged 18 and above who underwent endoscopic examination or treatment
• • All patients in the case group need to be pathologically confirmed as esophageal gastric junction adenocarcinoma, and a pathologist has conducted a standardized pathological evaluation of the tumor classification of the lesion, including the overall appearance, size, differentiation type, depth of infiltration, presence or absence of lymphatic/vascular invasion, surgical margin status, etc.
• • The endoscopic images of the control group patients need to be confirmed by biopsy pathology or at least two experienced endoscopists (with operating experience\>5000 cases) to jointly confirm that they have clear benign manifestations
• Exclusion Criteria:
• • The patient has a previous history of endoscopic treatment or surgery for the esophageal gastric junction.
• • Necessary clinical information cannot be provided during the research process (patient age, gender, lesion characteristics, endoscopic manifestations, endoscopic images, etc.)
• • Low quality endoscopic images, such as those severely affected by bleeding, aperture, blurring, defocusing, artifacts, or excessive mucus after biopsy.